Literature DB >> 25305751

Hypoglycemia, chronic kidney disease, and diabetes mellitus.

Mazen Alsahli1, John E Gerich2.   

Abstract

Hypoglycemia is a major problem associated with substantial morbidity and mortality in patients with diabetes and is often a major barrier to achieving optimal glycemic control. Chronic kidney disease not only is an independent risk factor for hypoglycemia but also augments the risk of hypoglycemia that is already present in people with diabetes. This article summarizes our current knowledge of the epidemiology, pathogenesis, and morbidity of hypoglycemia in patients with diabetes and chronic kidney disease and reviews therapeutic considerations in this situation. PubMed and MEDLINE were searched for literature published in English from January 1989 to May 2014 for diabetes mellitus, hypoglycemia, chronic kidney disease, and chronic renal insufficiency.
Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25305751     DOI: 10.1016/j.mayocp.2014.07.013

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  24 in total

1.  Salvianolic acid A attenuates kidney injury and inflammation by inhibiting NF-κB and p38 MAPK signaling pathways in 5/6 nephrectomized rats.

Authors:  Hong-Feng Zhang; Yan-Li Wang; Cheng Gao; Yan-Ting Gu; Jian Huang; Jin-Hui Wang; Jia-Hong Wang; Zhou Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-05-23       Impact factor: 6.150

Review 2.  Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.

Authors:  Vishnu Garla; Licy Yanes-Cardozo; Lillian F Lien
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

Review 3.  Effects of exercise on brain functions in diabetic animal models.

Authors:  Sun Shin Yi
Journal:  World J Diabetes       Date:  2015-05-15

4.  Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis.

Authors:  Francisco Herrera-Gómez; María Asensio-González; Anunciación González-López; F Javier Álvarez
Journal:  Front Pharmacol       Date:  2017-11-21       Impact factor: 5.810

5.  Epidemiology and outcomes of hypoglycemia in patients with advanced diabetic kidney disease on dialysis: A national cohort study.

Authors:  Yeh-Wen Chu; Hsuan-Ming Lin; Jhi-Joung Wang; Shih-Feng Weng; Chih-Ching Lin; Chih-Chiang Chien
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

6.  Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial.

Authors:  Thomas R Pieber; Harpreet S Bajaj; Simon R Heller; Ting Jia; Kamlesh Khunti; David C Klonoff; Steen Ladelund; Lawrence A Leiter; Lily Wagner; Athena Philis-Tsimikas
Journal:  Diabetes Obes Metab       Date:  2021-10-17       Impact factor: 6.408

7.  Diabetic Kidney Disease: Much Progress, But Still More to Do.

Authors:  Mark E Molitch
Journal:  Diabetes Spectr       Date:  2015-08

Review 8.  Hypoglycemia in Patients with Diabetes and Renal Disease.

Authors:  Mazen Alsahli; John E Gerich
Journal:  J Clin Med       Date:  2015-05-13       Impact factor: 4.241

Review 9.  Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.

Authors:  Merlin C Thomas; Päivi M Paldánius; Rajeev Ayyagari; Siew Hwa Ong; Per-Henrik Groop
Journal:  Diabetes Ther       Date:  2016-08-08       Impact factor: 2.945

10.  Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.

Authors:  Martin Haluzík; Alice Cheng; Dirk Müller-Wieland; Jukka Westerbacka; Zsolt Bosnyak; Felipe Lauand; Lydie Melas-Melt; Janaka Karalliedde; Julio Rosenstock; Geremia B Bolli
Journal:  Diabetes Obes Metab       Date:  2020-04-28       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.